Osteosarcoma is the most frequent highly malignant bone-tumor with a peak m
anifestation during the second and third decade of life. Although survival
rate increased up to 60-70% within the last 20 years, the problem of non-re
sponse to chemotherapy remains. Initial turner size and response to neoadju
vant chemotherapy are the most accepted prognostic factors used for postope
rative stratification of chemotherapy. The identification of patients with
a bad response to therapy at the time of diagnosis would facilitate already
a preoperative stratification of chemotherapy or a more aggressive regime
to increase survival. This review reflects on recently described molecular
markers but not on clinical parameters in human osteosarcoma with respect t
o their prognostic potential. This includes p53, the p-glycoprotein, the mu
ltidrug resistance gene, the humen epidermal growth Factor receptor and met
allothionein expression. Heat shock proteins have recently become important
in osteosarcoma because of their prognostic value and their role in drug r
esistance. A short overview of serological markers is also given. Further r
esults on drug resistance and survival may be provided by ongoing studies,
which investigate the role of proteins of the apoptotic and antiapoptotic f
amilies in human osteosarcoma. (C) 2001 Elsevier Science Ltd. All rights re
served.